Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.62 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | PLK1 | P53350 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416225 | 1.00 | NPC1 (0.70) | NPC1RAB9AMEN1KMT2ACES2 | |
| Hydrochloric Acid SCHEMBL30102161 | 0.98 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL27477217 | 0.87 | RAB9A (0.68) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL12871351 | 0.87 | NPC1 (0.90) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL3772232 | 0.86 | NPC1 (0.76) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL6997194 | 0.86 | NPC1 (0.71) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL16461033 | 0.85 | RAB9A (0.70) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL1012519 | 0.85 | NPC1 (0.70) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL667723 | 0.84 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ACES2 | |
| SCHEMBL21779857 | 0.84 | RAB9A (0.68) | NPC1RAB9AMEN1KMT2ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462616-A | Salts of compounds and crystalline forms thereof | 和记黄埔医药（上海）有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-114555558-B | Salts of compounds and crystalline forms thereof | 和记黄埔医药（上海）有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | claimed |
| EP-4045484-A1 | THE SALTS OF A COMPOUND AND THE CRYSTALLINE FORMS THEREOF | Hutchison Medipharma Limited (CN) | 2022-08-24 | — | — | EP | claimed |
| CN-114555558-A | Salts of compounds and crystalline forms thereof | 和记黄埔医药（上海）有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| WO-2007002361-A2 | 3-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-0206361-B1 | METHYL BENZOYLAMINO-2-HYDROXYACETATES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-04-26 | — | — | EP | disclosed |
| EP-0206361-A2 | Methyl benzoylamino-2-hydroxyacetates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-12-30 | — | — | EP | disclosed |
| EP-0206361-A2 | Methyl benzoylamino-2-hydroxyacetates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-12-30 | — | — | EP | disclosed |
| US-4447446-A | PESTICIDE, HERBICIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-05-08 | — | — | US | disclosed |
| EP-0059536-A2 | Amide derivatives, processes for preparing them, their use as fungicides and pesticidal compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-09-08 | — | — | EP | disclosed |
| US-3959269-A | TRANQUILIZERS, SEDATIVES | SANDOZ, INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | NPC1 2254/4885RAB9A 2434/4885MEN1 3584/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | NPC1 1540/4885RAB9A 2731/4885MEN1 3802/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | NPC1 3278/4885RAB9A 284/4885MEN1 3076/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | NPC1 2874/4885RAB9A 1423/4885MEN1 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.